- Home
- ASM vs VIR Comparison
ASM vs VIR Comparison
Compare ASM & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASM
- VIR
- Stock Information
- Founded
- ASM 1968
- VIR 2016
- Country
- ASM Canada
- VIR United States
- Employees
- ASM N/A
- VIR N/A
- Industry
- ASM Metal Mining
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- ASM Basic Materials
- VIR Health Care
- Exchange
- ASM Nasdaq
- VIR Nasdaq
- Market Cap
- ASM 612.8M
- VIR 706.4M
- IPO Year
- ASM N/A
- VIR 2019
- Fundamental
- Price
- ASM $4.58
- VIR $4.79
- Analyst Decision
- ASM Strong Buy
- VIR Strong Buy
- Analyst Count
- ASM 3
- VIR 10
- Target Price
- ASM $3.73
- VIR $26.80
- AVG Volume (30 Days)
- ASM 5.5M
- VIR 1.5M
- Earning Date
- ASM 11-11-2025
- VIR 10-30-2025
- Dividend Yield
- ASM N/A
- VIR N/A
- EPS Growth
- ASM 1940.36
- VIR N/A
- EPS
- ASM 0.11
- VIR N/A
- Revenue
- ASM $79,639,000.00
- VIR $19,000,000.00
- Revenue This Year
- ASM $33.26
- VIR N/A
- Revenue Next Year
- ASM $27.16
- VIR $9.65
- P/E Ratio
- ASM $44.67
- VIR N/A
- Revenue Growth
- ASM 53.08
- VIR N/A
- 52 Week Low
- ASM $0.85
- VIR $4.16
- 52 Week High
- ASM $4.75
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- ASM 63.68
- VIR 46.30
- Support Level
- ASM $4.00
- VIR $5.04
- Resistance Level
- ASM $4.30
- VIR $5.39
- Average True Range (ATR)
- ASM 0.24
- VIR 0.34
- MACD
- ASM -0.01
- VIR 0.01
- Stochastic Oscillator
- ASM 76.67
- VIR 31.08
About ASM Avino Silver & Gold Mines Ltd. (Canada)
Avino Silver & Gold Mines Ltd is a mineral resource company. It is engaged in the exploration, extraction, and processing of silver, gold, and copper and the acquisition, exploration, and advancement of mineral properties. The company generates majority of its revenues through the sale of Copper produced from its mines. Its project portfolio includes Avino; San Gonzalo; Oxide Tailings; Bralorne Gold and others.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.